U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358130) titled 'Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy' on Dec. 12, 2025.
Brief Summary: (1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
Study Start Date: Oct. 21, 2025
Study Type: INTERVENTIONAL
Condition:
Helicobacter Pylori Infection
Intervention:
DRUG: vonoprazan,...